Single ChAdOx1 nCoV-19 dose elicits stronger immune response in previously infected individuals than in SARS-CoV2 naive persons.

Fawzi EbrahimAsma AlboueishiInas M AlhudiriSalah Al TabalYosra LamamiSamira Al DwigenSondos AshlebNoha EjenfawiMohamed B MiladHayat RhoumahSalah Edin El Meshri Adam I Elzagheid

Published in: Immunity, inflammation and disease (2024)

Previous COVID-19 infection is associated with higher levels of SARS-CoV-2 antibodies following ChAdOx1 (AstraZeneca) vaccination. Our finding supports the notion that a single dose of ChAdOx1 nCoV-19 administered post-SARS-CoV-2 infection serves as an effective immune booster. This provides a possible rationale for a single-dose vaccine regimen for previously infected individuals.

Keyphrases

sars cov
respiratory syndrome coronavirus
immune response
clinical trial
hiv infected
dendritic cells
coronavirus disease